Metformin as a Disease-Modifying Agent in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review of Preclinical and Clinical Evidence.

Similarly, metformin was associated with slower rates of eGFR decline (MD = 2.94; 95% CI −1.93 to 7.81) and a reduced annual rate of eGFR loss (MD = 1.36; 95% CI −0.70 to 3.42), although these findings did not reach statistical significance [ 38 ].

also in 111,027 other papers